Synonyms: 36T125; D06672; Q324147; DB02638; HS-2028; CS-5769; EX-A3116; HY-12554; SC-47098; J-008213; Variquel; Remestyp; LS-161411; GTPL11241; CCG-270662; 14636-12-5; Glypressin; CHEBI:135905; Tox21_113374; SCHEMBL22699; TERLIPRESSIN; CHEMBL2135460; DTXSID7048952; Lucassin (TN); AKOS015994637; Terlipressina; Terlipressine; Glycylpressin; C52H74N16O15S2; CAS-14636-12-5; TerlipressinuM; NCGC00185754-01; EINECS 238-680-8; DSSTox_CID_28878; DSSTox_RID_83146; DSSTox_GSID_48952; Thymosin α1 Acetate; Thymosin al Acetate; Terlipressin Acetate; Terlipressin [BAN:INN]; Terlipressin (USAN/INN); Terlipressine [INN-French]; Terlipressinum [INN-Latin]; Terlipressina [INN-Spanish]; Terlipressin [USAN:INN:BAN]; Terlipressin Diacetate Salt; Terlipressin acetate, >=98%; Triglycyl-8-lysine-vasopressin; 1-Triglycyl-8-lysine Vasopressin; 130: PN: WO2010033207 SEQID: 171 claiMed protein; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin; H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2; Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (disulfide bridge 4:9)
CAS Registry number: 14636-12-5
EINECS：238-680-8
Molecular Formula: C₅₂H₇₄N₁₆O₁₅S₂
MW：1227.37

Boiling Point: 1824 °C at 760 mmHg
Flash Point: 1056.9 °C
Refractive index: 1.664
Density: 1.46 
Appearance: White powder

Pharmacological effects: Terlipressin is a novel long-acting synthetic vasopressin reagent,its chemical name is three glycyl lysine vasopressin, it is a prodrug, itself has no activity ,in vivo  , it removes three glycyl residues in its N-terminus by aminopeptidase, and slowly "releases" the active lysine vasopressin. It is this "slow release" mechanism that makes it maintain the smooth muscle contraction up to 10 hours after a single administration, wheras the same dose of vasopressin, it can maintain its activity for 20-40 minutes. On the other hand,because of the slow digestion,  lysine vasopressin in the circulation cannot reach toxic levels, and usage of  terlipressin is safer.

Pharmacological effect of terlipressin is splanchnic vascular smooth muscle contraction, and reduction of visceral blood flow (such as reducing blood flow in the mesentery, spleen, uterus, etc.), thereby reducing portal vein blood flow,and reducing portal pressure, on the other hand it may also reduce plasma renin concentration, thereby increasing the renal blood flow in patients with hepatorenal syndrome, to improve kidney function, and increase urine output. Terlipressin is currently the only drug which is able to increase mortality in patients with esophageal varices bleeding , it is previously mainly used in clinical for the treatment of variceal bleeding, in addition,terlipressin now has also been successfully used for liver and kidney integrated syndrome and refractory shock, it is also likely to play a useful role in the cardiopulmonary resuscitation . Compared with vasopressin, it has a lasting effect, and it does not cause dangerous complications, including promoting  fibrinolysis and severe complications in the cardiovascular systems, and the use of it is simple (available intravenous injection), it is more suitable for rescue and treatment of emergent and critical  patients.

Uses: N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin is an analogue of vasopressin used as a vasoactive drug in the management of hypotension. N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin is used norepinephrine-resistant septic shock and hepatorenal syndrome. N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin is also used in the treatment of acute variceal bleeding.